On November 24, 2020 Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL gene delivery platform, reported that it has entered into a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL platform technology (Press release, Symvivo, NOV 24, 2020, View Source [SID1234571681]). The agreement was facilitated by Johnson & Johnson Innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are gratified to be collaborating with Janssen on this important research," said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo. "This agreement continues to expand novel applications for the bacTRL platform."